0
     

Report Added
Report already added
Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter measurement, Blood Pressure measurement, Cardiac Imaging, Thorough QT Studies), End User (Pharmaceutical, Biopharma, CROs), Region - Global Forecast to 2027

Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter measurement, Blood Pressure measurement, Cardiac Imaging, Thorough QT Studies), End User (Pharmaceutical, Biopharma, CROs), Region - Global Forecast to 2027

The cardiac safety services market is projected to reach USD 1.0 Billion by 2027 from USD 0.6 Billion in 2022, at a CAGR of 11.2% during the forecast period. The increasing expenditure by pharmaceutical companies, alongside rising government spending is leading has driven the pace of R&D activity in this industry to develop new drugs. This will contribute to the need for numerous preclinical and clinical services during drug development, including cardiac safety evaluation.

“The Blood Pressure Measurement segment accounted for the second largest share of the type of services market in 2021”
Blood pressure monitoring is an essential part of cardiac safety services. Increasing R&D activities and stringent clinical trial regulations make blood pressure measurement a critical parameter from both an efficacy and a safety endpoint. This factor is expected to drive the growth of this market segment.

“The contract research organizations (CROs) accounted for the second largest share of the end user market in 2021”
CROs provide specialized services to pharmaceutical & biopharmaceutical companies at a low cost. As a result, many pharmaceutical & biopharmaceutical companies are outsourcing their drug discovery services to CROs. As cardiac safety services are critical in drug development processes, their adoption is expected to increase with an increase in outsourcing
Laboratory Corporation of America Holdings (US), Koninklijke Philips N.V. (Netherlands), Clario (US), Banook Group (France), IQVIA (US), Biotrial (France), Certara (US), Celerion (US), Medpace (US), Ncardia (Netherlands), Richmond Pharmacology (UK), PhysioStim (France), Shanghai Medicilon (China), Pharmaceutical Product Development (US), and SGS (Switzerland) are some of the major players operating in the market.

“Europe: The second largest share in the cardiac safety services market”
The European market includes Germany, the UK, France, Italy, Spain, and the RoE. It accounted for the second largest market share of the cardiac safety services market. Important considerations include demographic changes, such as the growing incidence of chronic diseases is expected to drive the market growth in the region

The primary interviews conducted for this report can be categorized as follows:
•By Respondent: Supply Side- 80% and Demand Side - 20%
•By Designation: Managers- 45%, CXOs and Director level - 30%, and Executives - 25%
•By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%

List of Companies Profiled in the Report:
•Laboratory Corporation of America Holdings (US)
• Koninklijke Philips N.V. (Netherlands)
•Clario (US)
•Banook Group (France)
•IQVIA (US)
•Biotrial (France)
•Certara (US)
•Celerion (US)
•Medpace (US)
•Ncardia (Netherlands)
•Richmond Pharmacology (UK)
•PhysioStim (France)
•Shanghai Medicilon (China)
•Pharmaceutical Product Development (US)
•SGS (Switzerland)

Research Coverage:
This report provides a detailed picture of the cardiac safety services market. It aims at estimating the size and future growth potential of the market across different segments such as the type, type of service, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cardiac safety services market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, challenges, trends, and opportunities.

Table of Content

1INTRODUCTION20
1.1STUDY OBJECTIVES20
1.2MARKET DEFINITION20
1.3STUDY SCOPE21
FIGURE 1CARDIAC SAFETY SERVICES MARKET21
1.4YEARS CONSIDERED21
1.5CURRENCY CONSIDERED22
1.6LIMITATIONS22
1.7STAKEHOLDERS22
2RESEARCH METHODOLOGY23
2.1RESEARCH DATA23
FIGURE 2RESEARCH DESIGN23
2.1.1SECONDARY DATA23
2.1.1.1Key data from secondary sources24
2.1.2PRIMARY DATA25
2.1.2.1Key data from primary sources25
2.1.2.2Key industry insights26
FIGURE 3BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION26
2.2MARKET SIZE ESTIMATION27
2.2.1BOTTOM-UP APPROACH27
FIGURE 4BOTTOM-UP APPROACH27
2.2.2TOP-DOWN APPROACH28
FIGURE 5TOP-DOWN APPROACH28
2.2.3GROWTH FORECAST28
2.3DATA TRIANGULATION29
FIGURE 6DATA TRIANGULATION METHODOLOGY29
2.4RESEARCH ASSUMPTIONS30
3EXECUTIVE SUMMARY31
FIGURE 7CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2022 VS. 2027 (USD MILLION)31
FIGURE 8CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)32
FIGURE 9CARDIAC SAFETY SERVICES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)32
FIGURE 10GEOGRAPHICAL SNAPSHOT OF CARDIAC SAFETY SERVICES MARKET33
4PREMIUM INSIGHTS34
4.1CARDIAC SAFETY SERVICES MARKET OVERVIEW34
FIGURE 11INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE MARKET GROWTH34
4.2NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET SHARE, BY TYPE AND COUNTRY (2021)35
FIGURE 12INTEGRATED SERVICES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 202135
4.3CARDIAC SAFETY SERVICES MARKET SHARE, BY TYPE OF SERVICE, 2022 VS. 202736
FIGURE 13ECG/HOLTER MEASUREMENT SERVICES SEGMENT TO DOMINATE MARKET IN 202736
4.4CARDIAC SAFETY SERVICES MARKET SHARE, BY END USER, 202236
FIGURE 14PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 202236
4.5CARDIAC SAFETY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES37
FIGURE 15EUROPEAN COUNTRIES TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD37
5MARKET OVERVIEW38
5.1INTRODUCTION38
5.2MARKET DYNAMICS38
FIGURE 16CARDIAC SAFETY SERVICES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES38
5.2.1DRIVERS39
5.2.1.1Growing R&D expenditure in pharmaceutical & biopharmaceutical industry39
FIGURE 17GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–202639
5.2.1.2Increased outsourcing of R&D activities39
FIGURE 18ACTIVE PHARMACEUTICAL DRUG PIPELINE, JANUARY 2011 TO JANUARY 202140
5.2.1.3Increasing number of clinical trials40
FIGURE 19INCREASING NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2021)41
5.2.2OPPORTUNITIES41
5.2.2.1Introduction of new technologies and methods41
5.2.2.2Growth in biosimilars and biologics markets42
5.2.3CHALLENGES42
5.2.3.1High cost of cardiac safety evaluation42
6CARDIAC SAFETY SERVICES MARKET, BY TYPE43
6.1INTRODUCTION44
TABLE 1CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)44
6.2INTEGRATED SERVICES44
6.2.1INTEGRATED SERVICES TO DOMINATE CARDIAC SAFETY SERVICES MARKET44
TABLE 2INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)44
TABLE 3NORTH AMERICA: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)45
TABLE 4EUROPE: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)45
TABLE 5ASIA PACIFIC: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)46
6.3STANDALONE SERVICES46
6.3.1STANDALONE SERVICES SEGMENT WITNESSING GROWTH DUE TO COST-EFFECTIVENESS46
TABLE 6STANDALONE CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)46
TABLE 7NORTH AMERICA: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)47
TABLE 8EUROPE: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)47
TABLE 9ASIA PACIFIC: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)48
7CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE49
7.1INTRODUCTION50
TABLE 10CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)50
7.2ECG/HOLTER MEASUREMENT SERVICES50
7.2.1ECG/HOLTER MEASUREMENT SERVICES SUPPORT R&D IN NOVEL METHODS FOR CLINICAL TRIALS AND DRUG DISCOVERY50
TABLE 11ECG/HOLTER MEASUREMENT SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)51
TABLE 12NORTH AMERICA: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)51
TABLE 13EUROPE: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)51
TABLE 14ASIA PACIFIC: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)52
7.3BLOOD PRESSURE MEASUREMENT SERVICES52
7.3.1INCREASING R&D ACTIVITIES TO DRIVE MARKET GROWTH52
TABLE 15BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)52
TABLE 16NORTH AMERICA: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)53
TABLE 17EUROPE: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)53
TABLE 18ASIA PACIFIC: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)53
7.4CARDIOVASCULAR IMAGING SERVICES54
7.4.1CARDIOVASCULAR IMAGING SERVICES HELP IN DRUG EVALUATION54
TABLE 19CARDIOVASCULAR IMAGING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)54
TABLE 20NORTH AMERICA: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)54
TABLE 21EUROPE: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)55
TABLE 22ASIA PACIFIC: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)55
7.5THOROUGH QT STUDIES55
7.5.1NEED TO MEET STRINGENT REGULATORY REQUIREMENTS TO DRIVE DEMAND FOR THOROUGH QT STUDIES55
TABLE 23THOROUGH QT STUDIES MARKET, BY REGION, 2020–2027 (USD MILLION)56
TABLE 24NORTH AMERICA: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)56
TABLE 25EUROPE: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)57
TABLE 26ASIA PACIFIC: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)57
7.6OTHER SERVICES58
TABLE 27OTHER CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)58
TABLE 28NORTH AMERICA: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)58
TABLE 29EUROPE: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)59
TABLE 30ASIA PACIFIC: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)59
8CARDIAC SAFETY SERVICES MARKET, BY END USER60
8.1INTRODUCTION61
TABLE 31CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)61
8.2PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES61
8.2.1INCREASING R&D BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE DEMAND FOR CARDIAC SAFETY SERVICES61
TABLE 32CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION)62
TABLE 33NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)62
TABLE 34EUROPE: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)62
TABLE 35ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)63
8.3CONTRACT RESEARCH ORGANIZATIONS63
8.3.1INCREASING OUTSOURCING OF DRUG DISCOVERY PROCESSES TO SUPPORT SEGMENT GROWTH63
TABLE 36CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION)63
TABLE 37NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)64
TABLE 38EUROPE: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)64
TABLE 39ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)65
9CARDIAC SAFETY SERVICES MARKET, BY REGION66
9.1INTRODUCTION67
TABLE 40CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)67
9.2NORTH AMERICA67
FIGURE 20NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET SNAPSHOT68
TABLE 41NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)69
TABLE 42NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)69
TABLE 43NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)69
TABLE 44NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)70
9.2.1US70
9.2.1.1US dominates global cardiac safety services market70
TABLE 45US: TOTAL NUMBER OF CLINICAL TRIALS (2019)70
TABLE 46US: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)71
TABLE 47US: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)71
TABLE 48US: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)71
9.2.2CANADA72
9.2.2.1Canada has high-quality clinical trial infrastructure and expertise72
TABLE 49CANADA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)72
TABLE 50CANADA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)73
TABLE 51CANADA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)73
9.3EUROPE73
FIGURE 21EUROPE: CARDIAC SAFETY SERVICES MARKET SNAPSHOT74
TABLE 52EUROPE: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)75
TABLE 53EUROPE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)75
TABLE 54EUROPE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)75
TABLE 55EUROPE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)76
9.3.1GERMANY76
9.3.1.1Availability of skilled staff and flexible labor laws have made Germany a popular EU hub for clinical trials76
TABLE 56GERMANY: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)77
TABLE 57GERMANY: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)77
TABLE 58GERMANY: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)77
9.3.2UK78
9.3.2.1Steady growth of pharmaceutical R&D expenditure indicates favorable prospects for cardiac safety services78
TABLE 59UK: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)78
TABLE 60UK: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)79
TABLE 61UK: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)79
9.3.3FRANCE79
9.3.3.1High clinical trial activity for cancer therapies to drive market growth79
TABLE 62FRANCE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)80
TABLE 63FRANCE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)80
TABLE 64FRANCE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)80
9.3.4ITALY81
9.3.4.1Strong pharma industry and availability of funding for drug development fuel market growth81
TABLE 65NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021)81
TABLE 66ITALY: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)82
TABLE 67ITALY: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)82
TABLE 68ITALY: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)82
9.3.5SPAIN83
9.3.5.1Growing investment in pharmaceutical R&D and a favorable climate for approvals boost market growth83
TABLE 69SPAIN: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)83
TABLE 70SPAIN: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)84
TABLE 71SPAIN: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)84
9.3.6REST OF EUROPE84
TABLE 72ROE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)85
TABLE 73ROE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)85
TABLE 74ROE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)86
9.4ASIA PACIFIC86
TABLE 75APAC: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)87
TABLE 76APAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)87
TABLE 77APAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)87
TABLE 78APAC: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)88
9.4.1CHINA88
9.4.1.1China dominates APAC market for cardiac safety services88
TABLE 79CHINA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)88
TABLE 80CHINA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)89
TABLE 81CHINA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)89
9.4.2JAPAN89
9.4.2.1Strong IP rights and supportive policies have strengthened R&D sector in Japan89
TABLE 82JAPAN: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)90
TABLE 83JAPAN: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)90
TABLE 84JAPAN: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)90
9.4.3INDIA91
9.4.3.1Lack of language barriers and availability of trained resources make India an attractive destination for clinical trials91
TABLE 85INDIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)91
TABLE 86INDIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)91
TABLE 87INDIA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)92
9.4.4AUSTRALIA92
9.4.4.1Favorable R&D tax incentives and cash rebates have driven clinical trial activity in Australia92
TABLE 88AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)92
TABLE 89AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)93
TABLE 90AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)93
9.4.5REST OF ASIA PACIFIC93
TABLE 91ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)94
TABLE 92ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)94
TABLE 93ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)94
9.5REST OF THE WORLD95
TABLE 94ROW: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)96
TABLE 95ROW: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)96
TABLE 96ROW: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)96
10COMPETITIVE LANDSCAPE97
10.1OVERVIEW97
FIGURE 22KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2019–202297
10.2MARKET PLAYER RANKING98
TABLE 97GLOBAL CARDIAC SAFETY SERVICES MARKET PLAYER RANKING, 202198
10.3COMPETITIVE LEADERSHIP MAPPING99
10.3.1VISIONARY LEADERS99
10.3.2DYNAMIC DIFFERENTIATORS99
10.3.3INNOVATORS99
10.3.4EMERGING COMPANIES99
FIGURE 23CARDIAC SAFETY SERVICES MARKET: COMPETITIVE LEADERSHIP MAPPING100
10.4COMPETITIVE SITUATION AND TRENDS101
10.4.1ACQUISITIONS101
TABLE 98ACQUISITIONS, 2019–2022101
10.4.2PARTNERSHIPS, ALLIANCES, AND AGREEMENTS101
TABLE 99PARTNERSHIPS, ALLIANCES, AND AGREEMENTS, 2019–2022101
10.4.3EXPANSIONS101
TABLE 100EXPANSIONS, 2019–2022101
10.4.4OTHER STRATEGIES102
TABLE 101OTHER STRATEGIES, 2019–2022102

11COMPANY PROFILES103
(Business overview, Products offered, Recent Developments, MNM view)*
11.1KEY PLAYERS103
11.1.1LABORATORY CORPORATION OF AMERICA HOLDINGS103
TABLE 102LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW103
FIGURE 24LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT104
11.1.2KONINKLIJKE PHILIPS106
TABLE 103KONINKLIJKE PHILIPS: BUSINESS OVERVIEW106
FIGURE 25KONINKLIJKE PHILIPS: COMPANY SNAPSHOT107
11.1.3CLARIO109
TABLE 104CLARIO: BUSINESS OVERVIEW109
11.1.4BANOOK GROUP111
TABLE 105BANOOK GROUP: BUSINESS OVERVIEW111
11.1.5IQVIA112
TABLE 106IQVIA: BUSINESS OVERVIEW112
FIGURE 26IQVIA: COMPANY SNAPSHOT113
11.1.6BIOTRIAL115
TABLE 107BIOTRIAL: BUSINESS OVERVIEW115
11.1.7CERTARA116
TABLE 108CERTARA: BUSINESS OVERVIEW116
FIGURE 27CERTARA: COMPANY SNAPSHOT117
11.1.8CELERION118
TABLE 109CELERION: BUSINESS OVERVIEW118
11.1.9MEDPACE119
TABLE 110MEDPACE: BUSINESS OVERVIEW119
FIGURE 28MEDPACE: COMPANY SNAPSHOT119
11.1.10NCARDIA121
TABLE 111NCARDIA: BUSINESS OVERVIEW121
11.1.11RICHMOND PHARMACOLOGY122
TABLE 112RICHMOND PHARMACOLOGY: BUSINESS OVERVIEW122
11.1.12PHYSIOSTIM123
TABLE 113PHYSIOSTIM: BUSINESS OVERVIEW123
11.2OTHER PLAYERS124
11.2.1SHANGHAI MEDICILON124
11.2.2PHARMACEUTICAL PRODUCT DEVELOPMENT LLC.124
11.2.3SGS S.A.125
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

12APPENDIX126
12.1DISCUSSION GUIDE126
12.2KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL129
12.3CUSTOMIZATION OPTIONS131
12.4RELATED REPORTS131
12.5AUTHOR DETAILS132

Report Title: Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter measurement, Blood Pressure measurement, Cardiac Imaging, Thorough QT Studies), End User (Pharmaceutical, Biopharma, CROs), Region - Global Forecast to 2027


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM